30results about How to "Prevent and reduce infection" patented technology

An implantable medical device has a medical unit, such as a pacemaker lead, and a casing at least partially enclosing the medical unit. The casing is formed of a base polymer such as a polyurethane, a polyurethane copolymer, a fluoropolymer and a polyolefin or a silicone rubber. The casing has biologically active agents covalently bonded to the base polymer. The biologically active agents can be attached to the base polymer as surface active end groups. As an alternative, the biologically active may be attached to a backbone the base polymer. As yet a further alternative, the biologically active agents may be attached to surface modifying end groups, which are in turn attached to the base polymer. Examples of suitable biologically active agents are microbial peptide agents, detergents, non-steroidal anti-inflammatory drugs, cations, amine-containing organosilicones, diphosphonates, fatty acids and fatty acid salts.

The present invention relates to an arthroscopy apparatus, comprising at least three elements selected from: a conventional arthroscopic lens (12), to which there is coupled a power supply device or capsule, in the inside of which is the power source (1), and a miniature camera (8), characterized by not comprising connecting cables.

The invention discloses a deep-cleaning, antibacterial and tooth-protecting mouth wash based on chitosan derivatives. The mouth wash is prepared from, by weight, 3% of chitosan derivatives, 5% of glycerol, 1.5% of xylitol, 2% of efficient solubilizer, 0.55% of citric acid, 0.3% of sodium citrate, 0.25% of malic acid, 0.12% of menthol, 0.15% of mint fragrance, 2% of propolis extracts, 3.5% of tea leaf extracts, 0.07% of caramel colour, 0.04% of saccharin sodium, 0.2% of chlorhexidine, 0.0003% of domiphen bromide and the balance deionized water. The invention provides the deep-cleaning, antibacterial and tooth-protecting mouth wash based on the chitosan derivatives and the preparation method of the mouth wash. The mouth wash prepared through the method has the functions of inhibiting bacteria, removing dental plaque and preventing oral ulcer, gingivitis and other oral diseases, and is good in antibacterial effect, quick in effect, free of toxic and side effects and comfortable in mouthfeel.

A sterilization apparatus for sterilizing air includes an outer housing having side walls extending between opposed bottom and top walls that, together, define an outer chamber. An inner housing is situated in the outer chamber and includes opposed top and bottom ends and having a wall structure that defines a sealed inner chamber extending therebetween. The wall structure includes at least one side wall that defines a transparent window. An inlet port is in communication with one end of the inner chamber and that directs unsterilized air into the inner chamber. An ultraviolet (“UV”) light source is positioned outwardly adjacent the window and configured to emit UV light through the window and into the inner chamber when energized so as to sterilize air in the inner chamber. An outlet port is in communication with another end of the inner chamber that directs sterilized air downstream from the inner chamber.

The present invention relates to the use of probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal Camplylobacter infection in a mammalian animal. It also relates to a method for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal, the method comprising administering to said animal, a probiotic microorganism. The invention also relates to a probiotic microorganism, for use in preventing or reducing gastrointestinal Campylobacter infection in a mammalian animal.

A composition for preventing or reducing harmful effects of protozoal infection is provided, comprising in one embodiment a yeast cell wall and a preparation derived from oregano. The composition may further include a mineral nutrient selected from selenium and/or zinc. The composition may also include a preparation derived from Yucca. Efficacy of the composition is shown against a variety of protozoal organisms.

The subject application provides a genetically modified recombinant facultative intracellular invasive bacterial pathogen (RFIIBP) or a recombinant attenuated Salmonella vaccine (RASV) strains encoding Zika virus (ZIKV) antigens. These strains exhibit high immunogenicity, complete safety, and attenuation, and are unable to persist or be shed in an infective or viable form. These RFIIBPs and RASVs also exhibit regulated delayed attenuation in vivo, regulated delayed in vivo synthesis of protective ZIKV antigens. Methods of inducing mucosal, systemic and cellular immunities in hosts are also provided and antibodies produced using the disclosed RFIIBPs and RASVs can comprise neutralizing antibodies against ZIKV that do not crossreact with Dengue virus (DENV).

The present invention pertains to a swine vaccine, in particular a vaccine comprising in combination live attenuated PRRS virus and inactivated Lawsonia intracellularis antigen, for the protection of a swine against an infection with PRRS virus and Lawsonia intracellularis bacteria. The invention also pertains to a method to protect a swine against an infection with PRRS virus and Lawsonia intracellularis bacteria using this vaccine.

The invention relates to the treatment of blood, blood products and organs for the removal and/or detoxification of amyloid-beta oligomers.

The present invention refers to a novel circovirus as causative agent of bone marrow aplasia with haemorrhagic disease in cattle. The present invention provides novel nucleic acid and protein sequences for diagnostic and therapeutic uses.

Embodiments of the disclosure encompass methods and compositions for maintaining a healthy fibrin network in an individual. The disclosure includes methods of targeting fibrin in an individual for the purpose of restoring fibrin that is subject to a level of fibrinolysis that is deleterious, such as excessive or reduced with respect to the general population. Such modifications of fibrin in an individual may include direct targeting of fibrin with the A2 domain of von Willebrand factor or a functional derivative or fragment thereof. In specific embodiments, the methods restore to a normal level any imbalance between coagulation and inflammation.

The present invention includes novel cyclic peptides of formula (I). The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same. The invention further provides a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and at least one cyclic compound of the invention. The invention further provides a method of treating, reducing, or preventing HIV-1 infection in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of at least one cyclic compound of the invention.

The invention relates to a limb wound shield, which is convenient to be used and has the protective effects for wounds. The invention comprises a bottom plate, an arc-shaped covering; two bottom edges of the covering are respectively provided with bottom plate frame; the bottom plate frame is integrated with the covering into a whole and the bottom plate is inwardly opened with a horizontal continuous groove from front to back; right and left sides of the bottom plate are located inside the horizontal continuous groove, and the bottom plate is connected with the bottom plate frame and is capable of sliding from front to back.

The present invention relates to the use of oligosaccharides derived from arabinoxylan for use in the prevention and treatment of gastrointestinal infection. More particularly the invention provides a method for preventing or reducing the gastrointestinal infection of a animal or human being with bacteria associated with gastroenteritis through the supplementation of their diets with the said oligosaccharides.

The invention relates to the field of mucosal immune cells, in particular to a method for inducing formation and proliferation of mucosal tissue resident memory T cells (TRM). The method at least comprises primary immunization of parts except intestinal tracts and enhanced immunization of the intestinal tracts, so that a large number of mucosal TRM are obtained and are used for preventing and treating mucosal invasion of pathogens. The primary immunization modes of the parts except the intestinal tracts at least comprise but are not limited to muscle inoculation, intracutaneous inoculation, subcutaneous inoculation, nasal drop inoculation, aerosol inhalation inoculation and sublingual inoculation. The immunity enhancing mode of the intestinal tract part comprises but is not limited to rectal intracavitary inoculation, and intestinal intracavitary inoculation is conducted through oral administration of enteric-coated vaccines.

The present invention pertains to a vaccine comprising non live Lawsonia intracellularis antigen and a pharmaceutically acceptable carrier for use in a method to reduce in a pig the negative impact on average daily weight gain (ADWG) associated with subclinical infection with Lawsonia intracellularis, by systemic administration of the vaccine to the pig.

The present invention pertains to a vaccine comprising non live Lawsonia intracellularis antigen and a pharmaceutically acceptable carrier for use in a method to reduce in a pig the shedding of Lawsonia intracellularis bacteria associated with subclinical infection with Lawsonia intracellularis, by systemic administration of the vaccine to the pig.